Notable Runner: Sangamo Biosciences, Inc. Stock Price Increases Today

Notable Runner: Sangamo Biosciences, Inc. Stock Price Increases Today

The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) is a huge mover today! About 472,089 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 49.14% since April 27, 2016 and is downtrending. It has underperformed by 54.37% the S&P500.
The move comes after 7 months positive chart setup for the $231.29M company. It was reported on Nov, 30 by Barchart.com. We have $3.38 PT which if reached, will make NASDAQ:SGMO worth $6.94 million more.

Analysts await Sangamo Biosciences, Inc. (NASDAQ:SGMO) to report earnings on February, 14. They expect $-0.25 earnings per share, down 25.00% or $0.05 from last year’s $-0.2 per share. After $-0.27 actual earnings per share reported by Sangamo Biosciences, Inc. for the previous quarter, Wall Street now forecasts -7.41% EPS growth.

Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage

Out of 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Sangamo Biosciences has been the topic of 12 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The rating was maintained by Wedbush on Wednesday, September 2 with “Buy”. The firm has “Overweight” rating given on Saturday, August 8 by JP Morgan. The firm has “Sell” rating given on Tuesday, September 8 by Zacks. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock has “Buy” rating given by Jefferies on Friday, October 23. On Wednesday, October 19 the stock rating was downgraded by PiperJaffray to “Neutral”. JP Morgan maintained the stock with “Buy” rating in Thursday, September 3 report. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) has “Buy” rating given on Wednesday, September 2 by Jefferies. The rating was maintained by Cowen & Co on Friday, September 4 with “Buy”. The rating was downgraded by Janney Capital on Thursday, August 4 to “Neutral”.

According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”

Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.40, from 0.81 in 2016Q1. The ratio is positive, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
Us Savings Bank De has 0% invested in the company for 5,000 shares. Pub Employees Retirement Association Of Colorado last reported 0% of its portfolio in the stock. Renaissance Technology Ltd owns 114,200 shares or 0% of their US portfolio. Moreover, Rhumbline Advisers has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 77,773 shares. Legal General Plc owns 13,267 shares or 0% of their US portfolio. Bourgeon Cap Ltd Liability Corp last reported 49,000 shares in the company. Moreover, Wellington Grp Limited Liability Partnership has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 85,500 shares. Baldwin Brothers Ma last reported 1,500 shares in the company. Jpmorgan Chase & holds 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 771 shares. Invesco Limited holds 0% or 23,513 shares in its portfolio. The New York-based Comml Bank Of Ny Mellon has invested 0.01% in Sangamo Biosciences, Inc. (NASDAQ:SGMO). The Massachusetts-based Cormorant Asset Mngmt Limited Com has invested 1.15% in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Fic Capital Inc owns 862,489 shares or 2.36% of their US portfolio. Voya Investment Management Lc last reported 1.18M shares in the company. Moreover, Dimensional Fund Limited Partnership has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 111,174 shares.

More important recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016, also Prnewswire.com published article titled: “Sangamo BioSciences Announces Participation At Upcoming Investor Conferences”, Prnewswire.com published: “Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX …” on September 06, 2016. More interesting news about Sangamo Biosciences, Inc. (NASDAQ:SGMO) was released by: Prnewswire.com and their article: “Sangamo BioSciences Announces New Gene Therapy Clinical Development Program …” with publication date: July 26, 2016.

SGMO Company Profile

Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment